Vanguard Group Inc. Has $37.55 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Vanguard Group Inc. lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,448,015 shares of the company's stock after selling 148,629 shares during the quarter. Vanguard Group Inc. owned about 4.65% of Viridian Therapeutics worth $37,553,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Dark Forest Capital Management LP acquired a new stake in shares of Viridian Therapeutics during the third quarter worth $264,000. Schonfeld Strategic Advisors LLC lifted its position in Viridian Therapeutics by 362.3% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 108,037 shares of the company's stock worth $1,657,000 after acquiring an additional 84,670 shares during the period. SG Americas Securities LLC grew its stake in Viridian Therapeutics by 150.5% during the 3rd quarter. SG Americas Securities LLC now owns 102,667 shares of the company's stock valued at $1,575,000 after purchasing an additional 61,676 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Viridian Therapeutics by 25.2% in the third quarter. Wellington Management Group LLP now owns 215,648 shares of the company's stock valued at $3,308,000 after purchasing an additional 43,349 shares during the period. Finally, Swiss National Bank raised its stake in shares of Viridian Therapeutics by 9.4% in the third quarter. Swiss National Bank now owns 66,400 shares of the company's stock worth $1,019,000 after purchasing an additional 5,700 shares during the last quarter.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock traded up $0.10 on Thursday, reaching $16.21. The company's stock had a trading volume of 587,257 shares, compared to its average volume of 946,004. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $1.02 billion, a P/E ratio of -3.05 and a beta of 1.07. The stock has a 50-day moving average price of $18.08 and a 200-day moving average price of $17.51. Viridian Therapeutics, Inc. has a 52-week low of $10.93 and a 52-week high of $30.30.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.15 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. Viridian Therapeutics's revenue was down 31.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.13) EPS. Analysts expect that Viridian Therapeutics, Inc. will post -4.39 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on VRDN. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Oppenheimer increased their price objective on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 19th. Royal Bank of Canada restated an "outperform" rating and set a $35.00 target price on shares of Viridian Therapeutics in a research report on Thursday, December 14th. B. Riley cut their price target on Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 21st. Finally, Wedbush lifted their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research note on Wednesday, February 28th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $36.60.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc acquired 476,190 shares of Viridian Therapeutics stock in a transaction on Monday, January 22nd. The stock was bought at an average price of $21.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the director now owns 1,839,954 shares in the company, valued at $38,639,034. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.43% of the company's stock.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.